ROSE Diagnostics announces addition of industry veteran Paul Gold to its Board of Directors

Carlsbad, California – 22 June 2024

ROSE Diagnostics is excited to announce the addition of Paul Gold to its Board of Directors in conjunction with closing its $1 million seed round. With nearly four decades of experience in aseptic technology and pharmaceutical operations, Paul brings valuable expertise to the company as it continues its mission to transform cancer diagnostic procedures.

Paul Gold, MS, is the owner and principal consultant at Pamigo Aseptic and formerly served as Director of Global Aseptic Technology at Pfizer, Inc., where he spearheaded key commercial and clinical initiatives across three continents. His hands-on leadership and accomplishments in aseptic drug product processes, coupled with his work on high-potency containment projects, will contribute significantly to ROSE Diagnostics’ efforts to innovate in healthcare diagnostics.

“We’re delighted to have Paul join our Board,” said Andrew Morris, CEO of ROSE Diagnostics. “His knowledge and proven leadership in the broader life sciences industry will play a pivotal role as we further our commitment to offering more effective and streamlined diagnostic services.”

For further inquiries, please contact: info@rose-dx.com